Ultragenyx Pharmaceutical Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Nominees: Daniel G. Welch

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Elect Director: Daniel G. Welch”): 66,301,426 for, 7,273,072 withheld, per its Form 8-K filed May 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 23,901,615 for, 1,865,849 withheld, 15 abstained.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: Nominees: Emil D. Kakkis, M.D., Ph.D.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Elect Director: Emil D. Kakkis, M.D., Ph.D.”): 72,517,613 for, 1,056,885 withheld, per its Form 8-K filed May 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 25,451,671 for, 315,806 withheld, 2 abstained.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: Nominees: Shehnaaz Suliman, M.D.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Elect Director: Shehnaaz Suliman, M.D.”): 65,801,638 for, 7,772,860 withheld, per its Form 8-K filed May 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 22,056,043 for, 3,711,420 withheld, 15 abstained.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: Approval of the Third Amended and Restated 2023 Incentive Plan.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Proposal 2: Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were as follows:”): 50,659,150 for, 22,888,600 against — passed, per its Form 8-K filed May 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 – Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Third A&R 2023 Plan.”
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 22,063,488 for, 3,698,928 against, 6,276 abstained.

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Description as filed by funds: Advisory (non-binding) vote to approve the compensation of our named executive officers.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its ”): 70,945,277 for, 2,594,517 against, per its Form 8-K filed May 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 82 managers: 25,650,442 for, 110,720 against, 6,276 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 248 managers: 38,074,629 for, 1,658,380 against, 284 not voted, 933,319 mixed. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 84,551,399 for, 221,802 against — passed, per its Form 8-K filed May 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 25,761,069 for, 134 against, 6,276 abstained.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.